A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.

IF 0.6 4区医学 Q4 ENDOCRINOLOGY & METABOLISM Neuro endocrinology letters Pub Date : 2022-09-16

Giuseppe Di Bella, Luigi Di Bella, Vittoria Borghetto, Ilaria Moscato, Elena Costanzo

{"title":"A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.","authors":"Giuseppe Di Bella, Luigi Di Bella, Vittoria Borghetto, Ilaria Moscato, Elena Costanzo","doi":"","DOIUrl":null,"url":null,"abstract":"Backgrounds: The prognosis of patients with osteosarcoma in many cases remains poor, and life expectancy with lung metastases is around 12 months. Chemotherapy and radiotherapy can only temporarily control neoplastic progression, followed by developing chemo and radioresistant tumours.Methods: This is a retrospective observational study on 15 patients diagnosed with osteosarcoma and treated by a multitherapy approach. The multitherapy consisted of somatostatin and analogous (octreotide) all-trans-retinoic acid (ATRA), β-Carotene, axerophthol dissolved in vitamin E, vitamin D, vitamin C, melatonin (MLT), proteoglycans, glycosaminoglycans, hydroxyurea, and sodium butyrate.Results: This multitherapy increased the survival rate and life quality, without overt toxicity, compared to the standard treatment for osteosarcomas. The agents in this approach have several functions. They exert antiproliferative, antiangiogenic, cytostatic, antioxidant, antimetastatic, and immunomodulating features. Moreover, the inclusion of ATRA, MLT, and sodium butyrate has reinforced antitumor properties on cancer stem cells. Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability.Findings: This multitherapy approach is effective against osteosarcoma.Interpretation: The multistrategy of this multitherapy therapy are inhibiting the proliferative-invasiveness and neoplastic angiogenesis, silencing the survival system of cancer stem cells, enhancing the immunomodulatory and antioxidant activities, improving vitality and efficiency of normal cells, and depressing the efficiency and vitality of neoplastic ones.","PeriodicalId":19098,"journal":{"name":"Neuro endocrinology letters","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Backgrounds: The prognosis of patients with osteosarcoma in many cases remains poor, and life expectancy with lung metastases is around 12 months. Chemotherapy and radiotherapy can only temporarily control neoplastic progression, followed by developing chemo and radioresistant tumours.

Methods: This is a retrospective observational study on 15 patients diagnosed with osteosarcoma and treated by a multitherapy approach. The multitherapy consisted of somatostatin and analogous (octreotide) all-trans-retinoic acid (ATRA), β-Carotene, axerophthol dissolved in vitamin E, vitamin D, vitamin C, melatonin (MLT), proteoglycans, glycosaminoglycans, hydroxyurea, and sodium butyrate.

Results: This multitherapy increased the survival rate and life quality, without overt toxicity, compared to the standard treatment for osteosarcomas. The agents in this approach have several functions. They exert antiproliferative, antiangiogenic, cytostatic, antioxidant, antimetastatic, and immunomodulating features. Moreover, the inclusion of ATRA, MLT, and sodium butyrate has reinforced antitumor properties on cancer stem cells. Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability.

Findings: This multitherapy approach is effective against osteosarcoma.

Interpretation: The multistrategy of this multitherapy therapy are inhibiting the proliferative-invasiveness and neoplastic angiogenesis, silencing the survival system of cancer stem cells, enhancing the immunomodulatory and antioxidant activities, improving vitality and efficiency of normal cells, and depressing the efficiency and vitality of neoplastic ones.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多疗法治疗骨肉瘤病例的回顾性观察研究:原理和效果。

背景:许多骨肉瘤患者的预后仍然很差，肺转移患者的预期寿命约为12个月。化疗和放疗只能暂时控制肿瘤的进展，随后发展为化疗和放射耐药肿瘤。方法:这是一项回顾性观察研究，对15例诊断为骨肉瘤的患者进行了多疗法治疗。综合治疗包括生长抑素和类似的(奥曲肽)全反式维甲酸(ATRA)、β-胡萝卜素、溶于维生素E、维生素D、维生素C、褪黑素(MLT)、蛋白聚糖、糖胺聚糖、羟基脲和丁酸钠。结果:与骨肉瘤的标准治疗相比，这种综合治疗提高了生存率和生活质量，没有明显的毒性。这种方法中的代理具有几个功能。它们具有抗增殖、抗血管生成、细胞抑制、抗氧化、抗转移和免疫调节的特点。此外，ATRA、MLT和丁酸钠的加入增强了对癌症干细胞的抗肿瘤特性。此外，非细胞溶解性和非细胞毒性的节拍性羟基脲剂量通过增强抗肿瘤能力来提高生物治疗效果。结果:这种综合治疗方法对骨肉瘤有效。解释:这种多疗法治疗的多策略是抑制肿瘤干细胞的增殖侵袭性和血管生成，沉默肿瘤干细胞的生存系统，增强免疫调节和抗氧化活性，提高正常细胞的活力和效率，抑制肿瘤细胞的效率和活力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuro endocrinology letters 医学-内分泌学与代谢

CiteScore

1.00

自引率

14.30%

发文量

审稿时长

6 months

期刊介绍： Neuroendocrinology Letters is an international, peer-reviewed interdisciplinary journal covering the fields of Neuroendocrinology, Neuroscience, Neurophysiology, Neuropsychopharmacology, Psychoneuroimmunology, Reproductive Medicine, Chronobiology, Human Ethology and related fields for RAPID publication of Original Papers, Review Articles, State-of-the-art, Clinical Reports and other contributions from all the fields covered by Neuroendocrinology Letters. Papers from both basic research (methodology, molecular and cellular biology, anatomy, histology, biology, embryology, teratology, normal and pathological physiology, biophysics, pharmacology, pathology and experimental pathology, biochemistry, neurochemistry, enzymology, chronobiology, receptor studies, endocrinology, immunology and neuroimmunology, animal physiology, animal breeding and ethology, human ethology, psychology and others) and from clinical research (neurology, psychiatry and child psychiatry, obstetrics and gynecology, pediatrics, endocrinology, immunology, cardiovascular studies, internal medicine, oncology and others) will be considered. The Journal publishes Original papers and Review Articles. Brief reports, Special Communications, proved they are based on adequate experimental evidence, Clinical Studies, Case Reports, Commentaries, Discussions, Letters to the Editor (correspondence column), Book Reviews, Congress Reports and other categories of articles (philosophy, art, social issues, medical and health policies, biomedical history, etc.) will be taken under consideration.